Clinical Trial Management System Market 2028 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Clinical Trial Management System (CTMS) Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Component (Software and Services), Product (Enterprise Based and Site Based), Delivery Mode (Web Based, Cloud Based and On Premise), End-user (Pharmaceutical & Biopharmaceutical Companies, Clinical Research Organizations [CROs], Medical Device Companies, and Other End Users), and Geography

Report Code: TIPHC00002241 | No. of Pages: 150 | Category: Healthcare IT | Status: Upcoming

A clinical trial management system CTMS is software system to accomplish clinical trial data operations generated by pharmaceutical and biotechnological companies. A CTMS manages up-to-date clinical data initiation from planning of research proposal to preparation, conducting and reporting generation. Clinical trial management system performs planning on budgets, report budgeting, clinical data management and report generation and accordingly the requirements of recipient companies vary from the future prospect.

The increasing research and development activities in the field of health science and clinical research is the foremost factor driving the demand for CTMS. The growing investments from public and private sectors and the introduction of conducive government policies are paving way for increased number of clinical trials, which is expected to boast the Clinical Trial Management System CTMS market during the forecast period.

The "Global Clinical Trial Management System CTMS Market Analysis to 2028" is a specialized and in-depth study of the medical device industry with a focus on the global market trend. The report aims to provide an overview of Global Clinical Trial Management System CTMS market with detailed market segmentation by component, product, delivery mode and end-user. The Global Clinical Trial Management System CTMS market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading market players and offers key trends and opportunities in the Clinical Trial Management System CTMS market.

The Global Clinical Trial Management System CTMS market is segmented on the basis of component, product, delivery mode, and end-user. The component segment includes, software and services. Based on product, the market is segmented as enterprise based and site based. Based on delivery mode, the market is segmented as, web based, cloud based and on premise. Based on end-user, the market is classified as, pharmaceutical & biopharmaceutical companies, clinical research organizations [CROs], medical device companies, and other end users.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Global Clinical Trial Management System CTMS market based on component, product, delivery mode and end-user. It also provides market size and forecast till 2028 for overall Clinical Trial Management System CTMS market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Clinical Trial Management System CTMS market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 13 counties globally along with current trend and opportunities prevailing in the region.

North America is expected to dominate this market in the forecast period due to favorable government initiatives, and support from government bodies. Also the raising awareness among people regarding diseases is expected to increase their participation in clinical trials. The Clinical Trial Management System CTMS market in Asia-Pacific is anticipated to grow during the forecast period owing to factors, such as huge, diverse patient pool, outsourcing of clinical trials to CROs, and rising healthcare facilities in the region.

The report analyzes factors affecting market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Clinical Trial Management System CTMS market in these regions.
The report also includes the profiles of key Clinical Trial Management System CTMS providers along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, products and services offered, financial information of last 3 years, key development in past five years. Some of the key players influencing the Clinical Trial Management System CTMS market are Oracle, Medidata Solutions Inc., PAREXEL International Corporation., MedNet Solutions, Inc., Bioclinica, BioOptronics, Inc., DATATRAK Int., ERT Clinical, FORTE, and ICON plc among others.

1. INTRODUCTION

1.1. SCOPE OF THE STUDY

1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE

1.3. MARKET SEGMENTATION

1.3.1 Clinical Trial - By Phase

1.3.2 Clinical Trial - By Study Design

1.3.3 Clinical Trial - By Indication

1.3.4 Clinical Trial - By Region

1.3.4.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. CLINICAL TRIAL LANDSCAPE

4.1. OVERVIEW

4.2. PEST ANALYSIS

4.2.1 North America - Pest Analysis

4.2.2 Europe - Pest Analysis

4.2.3 Asia-Pacific - Pest Analysis

4.2.4 Middle East and Africa - Pest Analysis

4.2.5 South and Central America - Pest Analysis

4.3. EXPERT OPINIONS

5. CLINICAL TRIAL - KEY MARKET DYNAMICS

5.1. KEY MARKET DRIVERS

5.2. KEY MARKET RESTRAINTS

5.3. KEY MARKET OPPORTUNITIES

5.4. FUTURE TRENDS

5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC

6. CLINICAL TRIAL - GLOBAL MARKET ANALYSIS

6.1. CLINICAL TRIAL - GLOBAL MARKET OVERVIEW

6.2. CLINICAL TRIAL - GLOBAL MARKET AND FORECAST TO 2028

6.3. MARKET POSITIONING/MARKET SHARE

7. CLINICAL TRIAL - REVENUE AND FORECASTS TO 2028 – PHASE

7.1. OVERVIEW

7.2. PHASE MARKET FORECASTS AND ANALYSIS

7.3. PHASE I

7.3.1. Overview

7.3.2. Phase I Market Forecast and Analysis

7.4. PHASE II

7.4.1. Overview

7.4.2. Phase II Market Forecast and Analysis

7.5. PHASE III

7.5.1. Overview

7.5.2. Phase III Market Forecast and Analysis

7.6. PHASE IV

7.6.1. Overview

7.6.2. Phase IV Market Forecast and Analysis

8. CLINICAL TRIAL - REVENUE AND FORECASTS TO 2028 – STUDY DESIGN

8.1. OVERVIEW

8.2. STUDY DESIGN MARKET FORECASTS AND ANALYSIS

8.3. INTERVENTIONAL

8.3.1. Overview

8.3.2. Interventional Market Forecast and Analysis

8.4. OBSERVATIONAL

8.4.1. Overview

8.4.2. Observational Market Forecast and Analysis

8.5. EXPANDED ACCESS

8.5.1. Overview

8.5.2. Expanded access Market Forecast and Analysis

9. CLINICAL TRIAL - REVENUE AND FORECASTS TO 2028 – INDICATION

9.1. OVERVIEW

9.2. INDICATION MARKET FORECASTS AND ANALYSIS

9.3. AUTOIMMUNE/INFLAMMATION

9.3.1. Overview

9.3.2. Autoimmune/inflammation Market Forecast and Analysis

9.4. PAIN MANAGEMENT

9.4.1. Overview

9.4.2. Pain management Market Forecast and Analysis

9.5. ONCOLOGY

9.5.1. Overview

9.5.2. Oncology Market Forecast and Analysis

9.6. CNS CONDITION

9.6.1. Overview

9.6.2. CNS condition Market Forecast and Analysis

9.7. DIABETES

9.7.1. Overview

9.7.2. Diabetes Market Forecast and Analysis

9.8. OBESITY

9.8.1. Overview

9.8.2. Obesity Market Forecast and Analysis

9.9. CARDIOVASCULAR

9.9.1. Overview

9.9.2. Cardiovascular Market Forecast and Analysis

9.10. OTHERS

9.10.1. Overview

9.10.2. Others Market Forecast and Analysis

10. CLINICAL TRIAL REVENUE AND FORECASTS TO 2028 – GEOGRAPHICAL ANALYSIS

10.1. NORTH AMERICA

10.1.1 North America Clinical Trial Overview

10.1.2 North America Clinical Trial Forecasts and Analysis

10.1.3 North America Clinical Trial Forecasts and Analysis - By Phase

10.1.4 North America Clinical Trial Forecasts and Analysis - By Study Design

10.1.5 North America Clinical Trial Forecasts and Analysis - By Indication

10.1.6 North America Clinical Trial Forecasts and Analysis - By Countries

10.1.6.1 United States Clinical Trial

10.1.6.1.1 United States Clinical Trial by Phase

10.1.6.1.2 United States Clinical Trial by Study Design

10.1.6.1.3 United States Clinical Trial by Indication

10.1.6.2 Canada Clinical Trial

10.1.6.2.1 Canada Clinical Trial by Phase

10.1.6.2.2 Canada Clinical Trial by Study Design

10.1.6.2.3 Canada Clinical Trial by Indication

10.1.6.3 Mexico Clinical Trial

10.1.6.3.1 Mexico Clinical Trial by Phase

10.1.6.3.2 Mexico Clinical Trial by Study Design

10.1.6.3.3 Mexico Clinical Trial by Indication

10.2. EUROPE

10.2.1 Europe Clinical Trial Overview

10.2.2 Europe Clinical Trial Forecasts and Analysis

10.2.3 Europe Clinical Trial Forecasts and Analysis - By Phase

10.2.4 Europe Clinical Trial Forecasts and Analysis - By Study Design

10.2.5 Europe Clinical Trial Forecasts and Analysis - By Indication

10.2.6 Europe Clinical Trial Forecasts and Analysis - By Countries

10.2.6.1 Germany Clinical Trial

10.2.6.1.1 Germany Clinical Trial by Phase

10.2.6.1.2 Germany Clinical Trial by Study Design

10.2.6.1.3 Germany Clinical Trial by Indication

10.2.6.2 France Clinical Trial

10.2.6.2.1 France Clinical Trial by Phase

10.2.6.2.2 France Clinical Trial by Study Design

10.2.6.2.3 France Clinical Trial by Indication

10.2.6.3 Italy Clinical Trial

10.2.6.3.1 Italy Clinical Trial by Phase

10.2.6.3.2 Italy Clinical Trial by Study Design

10.2.6.3.3 Italy Clinical Trial by Indication

10.2.6.4 Spain Clinical Trial

10.2.6.4.1 Spain Clinical Trial by Phase

10.2.6.4.2 Spain Clinical Trial by Study Design

10.2.6.4.3 Spain Clinical Trial by Indication

10.2.6.5 United Kingdom Clinical Trial

10.2.6.5.1 United Kingdom Clinical Trial by Phase

10.2.6.5.2 United Kingdom Clinical Trial by Study Design

10.2.6.5.3 United Kingdom Clinical Trial by Indication

10.3. ASIA-PACIFIC

10.3.1 Asia-Pacific Clinical Trial Overview

10.3.2 Asia-Pacific Clinical Trial Forecasts and Analysis

10.3.3 Asia-Pacific Clinical Trial Forecasts and Analysis - By Phase

10.3.4 Asia-Pacific Clinical Trial Forecasts and Analysis - By Study Design

10.3.5 Asia-Pacific Clinical Trial Forecasts and Analysis - By Indication

10.3.6 Asia-Pacific Clinical Trial Forecasts and Analysis - By Countries

10.3.6.1 Australia Clinical Trial

10.3.6.1.1 Australia Clinical Trial by Phase

10.3.6.1.2 Australia Clinical Trial by Study Design

10.3.6.1.3 Australia Clinical Trial by Indication

10.3.6.2 China Clinical Trial

10.3.6.2.1 China Clinical Trial by Phase

10.3.6.2.2 China Clinical Trial by Study Design

10.3.6.2.3 China Clinical Trial by Indication

10.3.6.3 India Clinical Trial

10.3.6.3.1 India Clinical Trial by Phase

10.3.6.3.2 India Clinical Trial by Study Design

10.3.6.3.3 India Clinical Trial by Indication

10.3.6.4 Japan Clinical Trial

10.3.6.4.1 Japan Clinical Trial by Phase

10.3.6.4.2 Japan Clinical Trial by Study Design

10.3.6.4.3 Japan Clinical Trial by Indication

10.3.6.5 South Korea Clinical Trial

10.3.6.5.1 South Korea Clinical Trial by Phase

10.3.6.5.2 South Korea Clinical Trial by Study Design

10.3.6.5.3 South Korea Clinical Trial by Indication

10.4. MIDDLE EAST AND AFRICA

10.4.1 Middle East and Africa Clinical Trial Overview

10.4.2 Middle East and Africa Clinical Trial Forecasts and Analysis

10.4.3 Middle East and Africa Clinical Trial Forecasts and Analysis - By Phase

10.4.4 Middle East and Africa Clinical Trial Forecasts and Analysis - By Study Design

10.4.5 Middle East and Africa Clinical Trial Forecasts and Analysis - By Indication

10.4.6 Middle East and Africa Clinical Trial Forecasts and Analysis - By Countries

10.4.6.1 South Africa Clinical Trial

10.4.6.1.1 South Africa Clinical Trial by Phase

10.4.6.1.2 South Africa Clinical Trial by Study Design

10.4.6.1.3 South Africa Clinical Trial by Indication

10.4.6.2 Saudi Arabia Clinical Trial

10.4.6.2.1 Saudi Arabia Clinical Trial by Phase

10.4.6.2.2 Saudi Arabia Clinical Trial by Study Design

10.4.6.2.3 Saudi Arabia Clinical Trial by Indication

10.4.6.3 U.A.E Clinical Trial

10.4.6.3.1 U.A.E Clinical Trial by Phase

10.4.6.3.2 U.A.E Clinical Trial by Study Design

10.4.6.3.3 U.A.E Clinical Trial by Indication

10.5. SOUTH AND CENTRAL AMERICA

10.5.1 South and Central America Clinical Trial Overview

10.5.2 South and Central America Clinical Trial Forecasts and Analysis

10.5.3 South and Central America Clinical Trial Forecasts and Analysis - By Phase

10.5.4 South and Central America Clinical Trial Forecasts and Analysis - By Study Design

10.5.5 South and Central America Clinical Trial Forecasts and Analysis - By Indication

10.5.6 South and Central America Clinical Trial Forecasts and Analysis - By Countries

10.5.6.1 Brazil Clinical Trial

10.5.6.1.1 Brazil Clinical Trial by Phase

10.5.6.1.2 Brazil Clinical Trial by Study Design

10.5.6.1.3 Brazil Clinical Trial by Indication

10.5.6.2 Argentina Clinical Trial

10.5.6.2.1 Argentina Clinical Trial by Phase

10.5.6.2.2 Argentina Clinical Trial by Study Design

10.5.6.2.3 Argentina Clinical Trial by Indication

11. INDUSTRY LANDSCAPE

11.1. MERGERS AND ACQUISITIONS

11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES

11.3. NEW PRODUCT LAUNCHES

11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

12. CLINICAL TRIAL , KEY COMPANY PROFILES

12.1. IQVIA

12.1.1. Key Facts

12.1.2. Business Description

12.1.3. Products and Services

12.1.4. Financial Overview

12.1.5. SWOT Analysis

12.1.6. Key Developments

12.2. PAREXEL INTERNATIONAL CORPORATION

12.2.1. Key Facts

12.2.2. Business Description

12.2.3. Products and Services

12.2.4. Financial Overview

12.2.5. SWOT Analysis

12.2.6. Key Developments

12.3. PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC

12.3.1. Key Facts

12.3.2. Business Description

12.3.3. Products and Services

12.3.4. Financial Overview

12.3.5. SWOT Analysis

12.3.6. Key Developments

12.4. CHARLES RIVER LABORATORY

12.4.1. Key Facts

12.4.2. Business Description

12.4.3. Products and Services

12.4.4. Financial Overview

12.4.5. SWOT Analysis

12.4.6. Key Developments

12.5. ICON PLC

12.5.1. Key Facts

12.5.2. Business Description

12.5.3. Products and Services

12.5.4. Financial Overview

12.5.5. SWOT Analysis

12.5.6. Key Developments

12.6. WUXI APPTEC INC

12.6.1. Key Facts

12.6.2. Business Description

12.6.3. Products and Services

12.6.4. Financial Overview

12.6.5. SWOT Analysis

12.6.6. Key Developments

12.7. PRA HEALTH SCIENCES

12.7.1. Key Facts

12.7.2. Business Description

12.7.3. Products and Services

12.7.4. Financial Overview

12.7.5. SWOT Analysis

12.7.6. Key Developments

12.8. SGS SA

12.8.1. Key Facts

12.8.2. Business Description

12.8.3. Products and Services

12.8.4. Financial Overview

12.8.5. SWOT Analysis

12.8.6. Key Developments

12.9. SYNEOS HEALTH

12.9.1. Key Facts

12.9.2. Business Description

12.9.3. Products and Services

12.9.4. Financial Overview

12.9.5. SWOT Analysis

12.9.6. Key Developments

12.10. CHILTERN INTERNATIONAL LTD

12.10.1. Key Facts

12.10.2. Business Description

12.10.3. Products and Services

12.10.4. Financial Overview

12.10.5. SWOT Analysis

12.10.6. Key Developments

13. APPENDIX

13.1. ABOUT THE INSIGHT PARTNERS

13.2. GLOSSARY OF TERMS

The List of Companies

1. Oracle
2. Medidata Solutions Inc.
3. PAREXEL International Corporation.
4. MedNet Solutions, Inc.
5. Bioclinica
6. BioOptronics, Inc.
7. DATATRAK Int.
8. ERT Clinical
9. FORTE
10. ICON plc
TIPHC00002241
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.


Speak To Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550
    GET FREE SAMPLE PDF

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount